As global markets navigate through a landscape of lower-than-expected U.S. inflation and fluctuating trade relations, investors are keenly observing the performance of small-cap indices, which have recently outpaced their larger counterparts. Penny stocks, often associated with smaller or newer companies, continue to present intriguing opportunities for growth at accessible price points. Despite being considered a niche area today, these stocks can offer substantial potential when backed by strong financial health and solid fundamentals.
Top 10 Penny Stocks Globally
| Name | Share Price | Market Cap | Rewards & Risks |
| Cloudpoint Technology Berhad (KLSE:CLOUDPT) | MYR0.725 | MYR385.41M | ✅ 4 ⚠️ 1 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.54 | HK$940.15M | ✅ 4 ⚠️ 1 View Analysis > |
| IVE Group (ASX:IGL) | A$2.79 | A$424.18M | ✅ 4 ⚠️ 3 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.55 | HK$2.16B | ✅ 4 ⚠️ 1 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD1.08 | SGD437.71M | ✅ 4 ⚠️ 2 View Analysis > |
| Deleum Berhad (KLSE:DELEUM) | MYR1.27 | MYR509.97M | ✅ 4 ⚠️ 1 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.52 | SGD13.85B | ✅ 5 ⚠️ 1 View Analysis > |
| Integrated Diagnostics Holdings (LSE:IDHC) | $0.5625 | $327M | ✅ 4 ⚠️ 2 View Analysis > |
| DXN Holdings Bhd (KLSE:DXN) | MYR0.525 | MYR2.61B | ✅ 5 ⚠️ 0 View Analysis > |
Click here to see the full list of 3,576 stocks from our Global Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Kaisa Health Group Holdings (SEHK:876)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Kaisa Health Group Holdings Limited is an investment holding company operating in the healthcare and dental sectors in China and internationally, with a market cap of HK$463.88 million.
Operations: The company generates revenue from its Dental Business, contributing HK$159.53 million, and its Health Care Business, which brings in HK$6.89 million.
Market Cap: HK$463.88M
Kaisa Health Group Holdings operates in the healthcare and dental sectors with a market cap of HK$463.88 million. Despite being unprofitable, it has reduced its losses over five years at 32.7% annually and remains debt-free, providing a stable financial base. The company reported HK$69.58 million in sales for the first half of 2025, showing a decrease from the previous year but also a significant reduction in net loss to HK$9.13 million from HK$24.26 million previously. Recent leadership changes include Ms. Luo Tingting's appointment as vice chairperson, potentially influencing future strategic direction.
- Click here and access our complete financial health analysis report to understand the dynamics of Kaisa Health Group Holdings.
- Explore historical data to track Kaisa Health Group Holdings' performance over time in our past results report.
V V Food & BeverageLtd (SHSE:600300)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: V V Food & Beverage Co., Ltd is involved in the research, development, production, and sale of food and beverage products both in China and internationally, with a market cap of CN¥5.61 billion.
Operations: V V Food & Beverage Co., Ltd does not report specific revenue segments.
Market Cap: CN¥5.61B
V V Food & Beverage Co., Ltd, with a market cap of CN¥5.61 billion, has shown improved net profit margins at 12.1% and high-quality earnings despite a decline in sales from CN¥2,688.7 million to CN¥2,387.7 million over the past nine months ending September 2025. The company maintains strong financial health with more cash than total debt and short-term assets of CN¥2.2 billion covering both short and long-term liabilities comfortably. Earnings growth of 26.4% last year outpaced the industry average significantly, though recent revenue figures indicate challenges in maintaining previous sales levels.
- Navigate through the intricacies of V V Food & BeverageLtd with our comprehensive balance sheet health report here.
- Gain insights into V V Food & BeverageLtd's historical outcomes by reviewing our past performance report.
Dezhan Healthcare (SZSE:000813)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Dezhan Healthcare Company Limited focuses on the research, development, manufacture, and sale of cardiovascular and cerebrovascular drugs in China, with a market cap of CN¥8.72 billion.
Operations: Dezhan Healthcare Company Limited has not reported any specific revenue segments.
Market Cap: CN¥8.72B
Dezhan Healthcare, with a market cap of CN¥8.72 billion, faces challenges as it reported a net loss of CN¥61.03 million for the nine months ending September 2025, down from a net income the previous year. Despite being unprofitable and experiencing declining earnings over the past five years, its financial position is bolstered by having more cash than total debt and short-term assets of CN¥3.2 billion covering liabilities effectively. Recent board changes may impact strategic direction, though management's average tenure is relatively short at 2.2 years, indicating potential volatility in leadership stability moving forward.
- Jump into the full analysis health report here for a deeper understanding of Dezhan Healthcare.
- Assess Dezhan Healthcare's previous results with our detailed historical performance reports.
Turning Ideas Into Actions
- Dive into all 3,576 of the Global Penny Stocks we have identified here.
- Interested In Other Possibilities? We've found 24 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Dezhan Healthcare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com